Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wolfgang Bartsch is active.

Publication


Featured researches published by Wolfgang Bartsch.


European Journal of Clinical Pharmacology | 1990

Pharmacological characteristics of the stereoisomers of carvedilol

Wolfgang Bartsch; Gisbert Sponer; Klaus Prof. Strein; Bernd Muller-Beckmann; Lothar Kling; Erwin Böhm; U. Martin; H. O. Borbe

SummaryThe racemic compound carvedilol possesses two complementary pharmacological effects, vasodilation and β-blockade. TheR- andS-enantiomers of carvedilol and the racemate were investigated with respect to the β-blocking, vasodilating, and hypotensive actions. In agreement with results obtained with other β-blockers, only theS-enantiomer of carvedilol exerts β-blocking effects. In contrast, no substantial difference between the enantiomers could be seen with respect to α-blockade. The greater hypotensive activity ofS-carvedilol may be attributed to β-blockade, which inhibits counter-regulatory mechanisms provoked by vasodilation. From these results it is concluded that there is a rationale for using carvedilol as the racemate. Using theS-enantiomer would lead to relatively strong β-blockade with only a weak vasodilating effect. TheR-enantiomer alone would act only as a hypotensive agent without β-blockade.


Journal of Pharmacological Methods | 1981

A method for evaluating postural hypotension in conscious rabbits as a model to predict effects of drugs in man

Gisbert Sponer; G. Mannesmann; Wolfgang Bartsch; Karl Dietmann

Because of the importance of postural hypotension as a side effect of antihypertensive drugs in man, an experimental model has been developed that permits the investigation of blood pressure response to tilting. Conscious rabbits were placed on a tilting table and tilted rapidly from horizontal to vertical position. Blood pressure was recorded continuously throughout the whole period. The individual orthostatic reaction was expressed as an orthostatic index. The experimental data obtained with guancydine, clonidine, guanethidine, prazosin, and dihydralazine were compared with clinical observations with regard to the impairment of orthostatic reaction; dihydralazine did not agree, but there was a good agreement for guancydine, clonidine, guanethidine, and prazosin. Although complete agreement between the experimental data and clinical observations does not exist, the model seems to be sufficient to differentiate between drugs with low or high potential for postural hypotension.


Toxicology and Applied Pharmacology | 1984

Differences in the nitrite ion formation and the toxicological findings between isosorbide dinitrate and isosorbide-5-mononitrate.

Klaus Prof. Strein; Wolfgang Bartsch; Gisbert Sponer; Bernd Muller-Beckmann; P. Lexa

In the metabolism of isosorbide dinitrate (ISDN), fast denitration with the formation of nitrite ions and a mononitrate plays an important role. In contrast, the denitration of isosorbide-5-mononitrate (IS-5-MN) to isosorbide is very slow. Accordingly po administration of high doses of ISDN (92.5 and 236 mg/kg) in conscious dogs led to maximum nitrite concentrations in the blood of 0.9 and 3.3 mg/liter, respectively. In contrast, with equimolar doses of IS-5-MN (75 and 191 mg/kg) we were able to detect nitrite ions reliably only at the higher dose and this gave a maximum blood concentration of 0.4 mg/liter. The rise in nitrite ion concentration is followed by the formation of methemoglobin. As is known from the literature, there is a rise in the activity of alkaline phosphatase in the serum of rabbits in addition to methemoglobin formation following repeated administration of sodium nitrite. So we have specifically investigated whether this is also the case following ISDN and IS-5-MN administration. On po administration of 236 mg/kg ISDN/day to dogs, there was a continuous rise in alkaline phosphatase from about the 20th day onward which we did not observe after the equimolar dose of IS-5-MN (191 mg/kg). NaNO2, 35 mg/kg po, led to a comparable maximal rise in methemoglobin to that obtained with 236 mg/kg ISDN. Repeated po administration of 35 mg/kg NaNO2/day also caused a rise in alkaline phosphatase. It is concluded that the formation of nitrite ions from ISDN is the reason for the rise in methemoglobin and alkaline phosphatase. The lower formation of nitrite ions from IS-5-MN can also be of clinical importance, at least in certain cases.


Archive | 1983

Pharmakologisches Spektrum des Metipranolol und Erfahrungen der klinischen Anwendung

Wolfgang Bartsch; Gisbert Sponer; Klaus Prof. Strein

In den letzten Jahren haben sich β-Rezeptorenblocker in der Therapie des Glaukoms einen zwar nicht unumstrittenen, jedoch festen Platz erworben. Diese Indikation hat sich ganz unerwartet ergeben. Messungen des Augendruckes bei Glaukompatienten, die wegen anderer Erkrankungen, z. B. Angina pectoris oder Hypertonie mit β-Rezeptorenblockern oral behandelt wurden, liesen einen augeninnendrucksenkenden, d. h. therapeutischen Effekt erkennen [1, 2].


Archive | 1984

Pharmacological Spectrum of Metipranolol and Experience in Clinical Use

Wolfgang Bartsch; Gisbert Sponer; Klaus Prof. Strein

In the past few years β-receptor blockers have assumed a firm although not entirely undisputed position in the treatment of glaucomas. This indication came quite unexpectedly. When the ocular pressure of glaucoma patients who were receiving oral treatment with β-receptor blocking agents for other diseases, e. g. angina pectoris or hypertension, was measured a pressure reducing, i. e. therapeutic effect, was revealed [1, 2].


Archive | 1985

Indolin-2-one derivatives preparation thereof and intermediates for the preparation thereof

Helmut Michel; Klaus Marzenell; Wolfgang Kampe; Wolfgang Bartsch; Wolfgang Schaumann


Archive | 1986

Beta-blocking oxindole derivatives

Helmut Michel; Wolfgang Kampe; Klaus Strein; Wolfgang Bartsch


Archive | 1984

Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte

Helmut Michel; Wolfgang Kampe; Klaus Strein; Wolfgang Bartsch


Archive | 1972

Tricyclische diphenylamin-derivate und verfahren zur herstellung derselben

Herbert Leinert; Alfred Dr Rer Nat Popelak; Max Dr Rer Nat Thiel; Wolfgang Bartsch; Wolfgang Schaumann


Archive | 1985

Nitroxy amino propanols for treating heart and circulatory diseases

Herbert Simon; Helmut Michel; Walter-Gunar Friebe; Wolfgang Bartsch

Collaboration


Dive into the Wolfgang Bartsch's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge